Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients.

Nimmo C, Millard J, Brien K, Moodley S, van Dorp L, Lutchminarain K, Wolf A, Grant AD, Balloux F, Pym AS, Padayatchi N, O'Donnell M.

Eur Respir J. 2020 Feb 14. pii: 1902383. doi: 10.1183/13993003.02383-2019. [Epub ahead of print] No abstract available.

PMID:
32060065
2.

N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.

Mthiyane T, Millard J, Adamson J, Balakrishna Y, Connolly C, Owen A, Rustomjee R, Dheda K, McIlleron H, Pym AS.

Antimicrob Agents Chemother. 2020 Jan 21. pii: AAC.02376-19. doi: 10.1128/AAC.02376-19. [Epub ahead of print]

3.

Publisher Correction: Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis.

Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, Ahmed M, Nhamoyebonde S, Rangel-Moreno J, Ogongo P, Lu L, Ramsuran D, de la Luz Garcia-Hernandez M, Ulland TK, Darby M, Park E, Karim F, Melocchi L, Madansein R, Dullabh KJ, Dunlap M, Marin-Agudelo N, Ebihara T, Ndung'u T, Kaushal D, Pym AS, Kolls JK, Steyn A, Zúñiga J, Horsnell W, Yokoyama WM, Shalek AK, Kløverpris HN, Colonna M, Leslie A, Khader SA.

Nature. 2019 Aug;572(7768):E10. doi: 10.1038/s41586-019-1458-y.

PMID:
31337923
4.

Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis.

Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, Ahmed M, Nhamoyebonde S, Rangel-Moreno J, Ogongo P, Lu L, Ramsuran D, de la Luz Garcia-Hernandez M, K Ulland T, Darby M, Park E, Karim F, Melocchi L, Madansein R, Dullabh KJ, Dunlap M, Marin-Agudelo N, Ebihara T, Ndung'u T, Kaushal D, Pym AS, Kolls JK, Steyn A, Zúñiga J, Horsnell W, Yokoyama WM, Shalek AK, Kløverpris HN, Colonna M, Leslie A, Khader SA.

Nature. 2019 Jun;570(7762):528-532. doi: 10.1038/s41586-019-1276-2. Epub 2019 Jun 5. Erratum in: Nature. 2019 Jul 24;:.

5.

Correction to: Whole genome sequencing Mycobacterium tuberculosis directly from sputum identifies more genetic diversity than sequencing from culture.

Nimmo C, Shaw LP, Doyle R, Williams R, Brien K, Burgess C, Breuer J, Balloux F, Pym AS.

BMC Genomics. 2019 May 29;20(1):433. doi: 10.1186/s12864-019-5841-8.

6.

Whole genome sequencing Mycobacterium tuberculosis directly from sputum identifies more genetic diversity than sequencing from culture.

Nimmo C, Shaw LP, Doyle R, Williams R, Brien K, Burgess C, Breuer J, Balloux F, Pym AS.

BMC Genomics. 2019 May 20;20(1):389. doi: 10.1186/s12864-019-5782-2. Erratum in: BMC Genomics. 2019 May 29;20(1):433.

7.

Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons.

van der Heijden YF, Karim F, Chinappa T, Mufamadi G, Zako L, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):871-877. doi: 10.5588/ijtld.17.0766.

8.

Whole-Transcriptome and -Genome Analysis of Extensively Drug-Resistant Mycobacterium tuberculosis Clinical Isolates Identifies Downregulation of ethA as a Mechanism of Ethionamide Resistance.

de Welzen L, Eldholm V, Maharaj K, Manson AL, Earl AM, Pym AS.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01461-17. doi: 10.1128/AAC.01461-17. Print 2017 Dec.

9.

A comprehensive characterization of PncA polymorphisms that confer resistance to pyrazinamide.

Yadon AN, Maharaj K, Adamson JH, Lai YP, Sacchettini JC, Ioerger TR, Rubin EJ, Pym AS.

Nat Commun. 2017 Sep 19;8(1):588. doi: 10.1038/s41467-017-00721-2.

10.

Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.

van der Heijden YF, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS.

Int J Tuberc Lung Dis. 2017 Jun 1;21(6):670-676. doi: 10.5588/ijtld.16.0843.

11.

Correction: Intracellular growth of Mycobacterium tuberculosis after macrophage cell death leads to serial killing of host cells.

Mahamed D, Boulle M, Ganga Y, Mc Arthur C, Skroch S, Oom L, Catinas O, Pillay K, Naicker M, Rampersad S, Mathonsi C, Hunter J, Wong EB, Suleman M, Sreejit G, Pym AS, Lustig G, Sigal A.

Elife. 2017 May 5;6. pii: e28205. doi: 10.7554/eLife.28205. No abstract available.

12.

Intracellular growth of Mycobacterium tuberculosis after macrophage cell death leads to serial killing of host cells.

Mahamed D, Boulle M, Ganga Y, Mc Arthur C, Skroch S, Oom L, Catinas O, Pillay K, Naicker M, Rampersad S, Mathonsi C, Hunter J, Wong EB, Suleman M, Sreejit G, Pym AS, Lustig G, Sigal A.

Elife. 2017 Jan 28;6. pii: e22028. doi: 10.7554/eLife.22028. Erratum in: Elife. 2017 May 05;6:.

13.

Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.

Manson AL, Cohen KA, Abeel T, Desjardins CA, Armstrong DT, Barry CE 3rd, Brand J; TBResist Global Genome Consortium, Chapman SB, Cho SN, Gabrielian A, Gomez J, Jodals AM, Joloba M, Jureen P, Lee JS, Malinga L, Maiga M, Nordenberg D, Noroc E, Romancenco E, Salazar A, Ssengooba W, Velayati AA, Winglee K, Zalutskaya A, Via LE, Cassell GH, Dorman SE, Ellner J, Farnia P, Galagan JE, Rosenthal A, Crudu V, Homorodean D, Hsueh PR, Narayanan S, Pym AS, Skrahina A, Swaminathan S, Van der Walt M, Alland D, Bishai WR, Cohen T, Hoffner S, Birren BW, Earl AM.

Nat Genet. 2017 Mar;49(3):395-402. doi: 10.1038/ng.3767. Epub 2017 Jan 16.

14.

Paradoxical Hypersusceptibility of Drug-resistant Mycobacteriumtuberculosis to β-lactam Antibiotics.

Cohen KA, El-Hay T, Wyres KL, Weissbrod O, Munsamy V, Yanover C, Aharonov R, Shaham O, Conway TC, Goldschmidt Y, Bishai WR, Pym AS.

EBioMedicine. 2016 Jul;9:170-179. doi: 10.1016/j.ebiom.2016.05.041. Epub 2016 Jun 1.

15.

Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in D-cycloserine resistance.

Desjardins CA, Cohen KA, Munsamy V, Abeel T, Maharaj K, Walker BJ, Shea TP, Almeida DV, Manson AL, Salazar A, Padayatchi N, O'Donnell MR, Mlisana KP, Wortman J, Birren BW, Grosset J, Earl AM, Pym AS.

Nat Genet. 2016 May;48(5):544-51. doi: 10.1038/ng.3548. Epub 2016 Apr 11.

16.

Assessing the utility of Xpert(®) MTB/RIF as a screening tool for patients admitted to medical wards in South Africa.

Heidebrecht CL, Podewils LJ, Pym AS, Cohen T, Mthiyane T, Wilson D.

Sci Rep. 2016 Jan 20;6:19391. doi: 10.1038/srep19391.

17.

Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.

Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B; TMC207-C209 Study Group.

Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.

18.

Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.

Cohen KA, Abeel T, Manson McGuire A, Desjardins CA, Munsamy V, Shea TP, Walker BJ, Bantubani N, Almeida DV, Alvarado L, Chapman SB, Mvelase NR, Duffy EY, Fitzgerald MG, Govender P, Gujja S, Hamilton S, Howarth C, Larimer JD, Maharaj K, Pearson MD, Priest ME, Zeng Q, Padayatchi N, Grosset J, Young SK, Wortman J, Mlisana KP, O'Donnell MR, Birren BW, Bishai WR, Pym AS, Earl AM.

PLoS Med. 2015 Sep 29;12(9):e1001880. doi: 10.1371/journal.pmed.1001880. eCollection 2015 Sep.

19.

Molecular Basis of Drug Resistance in Mycobacterium tuberculosis.

Cohen KA, Bishai WR, Pym AS.

Microbiol Spectr. 2014 Jun;2(3). doi: 10.1128/microbiolspec.MGM2-0036-2013. Review.

PMID:
26103975
20.

Fatal nosocomial MDR TB identified through routine genetic analysis and whole-genome sequencing.

Williams OM, Abeel T, Casali N, Cohen K, Pym AS, Mungall SB, Desjardins CA, Banerjee A, Drobniewski F, Earl AM, Cooke GS.

Emerg Infect Dis. 2015 Jun;21(6):1082-4. doi: 10.3201/eid2106.141903. No abstract available.

21.

Revisiting Anti-tuberculosis Activity of Pyrazinamide in Mice.

Almeida DV, Tyagi S, Li S, Wallengren K, Pym AS, Ammerman NC, Bishai WR, Grosset JH.

Mycobact Dis. 2014 May 5;4:145.

22.

Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility.

Streicher EM, Maharaj K, York T, Van Heerden C, Barnard M, Diacon A, Mendel CM, Bosman ME, Hepple JA, Pym AS, Warren RM, van Helden PD.

J Clin Microbiol. 2014 Nov;52(11):4056-7. doi: 10.1128/JCM.02438-14. Epub 2014 Aug 27.

23.

High rates of potentially infectious tuberculosis and multidrug-resistant tuberculosis (MDR-TB) among hospital inpatients in KwaZulu Natal, South Africa indicate risk of nosocomial transmission.

Bantubani N, Kabera G, Connolly C, Rustomjee R, Reddy T, Cohen T, Pym AS.

PLoS One. 2014 Mar 13;9(3):e90868. doi: 10.1371/journal.pone.0090868. eCollection 2014.

24.

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.

Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, Ammerman NC, Pym AS, Wallengren K, Hafner R, Lalloo U, Swindells S, Bishai WR.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15001-5. doi: 10.1073/pnas.1203636109. Epub 2012 Aug 27.

25.

International spread of MDR TB from Tugela Ferry, South Africa.

Cooke GS, Beaton RK, Lessells RJ, John L, Ashworth S, Kon OM, Williams OM, Supply P, Moodley P, Pym AS.

Emerg Infect Dis. 2011 Nov;17(11):2035-7. doi: 10.3201/eid1711.110291.

26.

Systematic genetic nomenclature for type VII secretion systems.

Bitter W, Houben EN, Bottai D, Brodin P, Brown EJ, Cox JS, Derbyshire K, Fortune SM, Gao LY, Liu J, Gey van Pittius NC, Pym AS, Rubin EJ, Sherman DR, Cole ST, Brosch R.

PLoS Pathog. 2009 Oct;5(10):e1000507. doi: 10.1371/journal.ppat.1000507. Epub 2009 Oct 30. No abstract available.

27.

Proteome analysis of the plasma membrane of Mycobacterium tuberculosis.

Sinha S, Arora S, Kosalai K, Namane A, Pym AS, Cole ST.

Comp Funct Genomics. 2002;3(6):470-83. doi: 10.1002/cfg.211.

28.

Evaluation of new antituberculosis drugs in mouse models.

Davies GR, Pym AS, Mitchison DA, Nuermberger EL, Grosset JH.

Antimicrob Agents Chemother. 2007 Jan;51(1):403; author reply 403-4. No abstract available.

29.

Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis.

Gagneux S, Burgos MV, DeRiemer K, Encisco A, Muñoz S, Hopewell PC, Small PM, Pym AS.

PLoS Pathog. 2006 Jun;2(6):e61. Epub 2006 Jun 16.

30.

Does resistance to pyrazinamide accurately indicate the presence of Mycobacterium bovis?

de Jong BC, Onipede A, Pym AS, Gagneux S, Aga RS, DeRiemer K, Small PM.

J Clin Microbiol. 2005 Jul;43(7):3530-2.

31.

Genomic deletions classify the Beijing/W strains as a distinct genetic lineage of Mycobacterium tuberculosis.

Tsolaki AG, Gagneux S, Pym AS, Goguet de la Salmoniere YO, Kreiswirth BN, Van Soolingen D, Small PM.

J Clin Microbiol. 2005 Jul;43(7):3185-91.

32.

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.

Williams A, Hatch GJ, Clark SO, Gooch KE, Hatch KA, Hall GA, Huygen K, Ottenhoff TH, Franken KL, Andersen P, Doherty TM, Kaufmann SH, Grode L, Seiler P, Martin C, Gicquel B, Cole ST, Brodin P, Pym AS, Dalemans W, Cohen J, Lobet Y, Goonetilleke N, McShane H, Hill A, Parish T, Smith D, Stoker NG, Lowrie DB, Källenius G, Svenson S, Pawlowski A, Blake K, Marsh PD.

Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):29-38. Epub 2005 Jan 20.

PMID:
15687025
33.

High-throughput method for detecting genomic-deletion polymorphisms.

Goguet de la Salmonière YO, Kim CC, Tsolaki AG, Pym AS, Siegrist MS, Small PM.

J Clin Microbiol. 2004 Jul;42(7):2913-8.

34.

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.

Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, Griffiths KE, Marchal G, Leclerc C, Cole ST.

Nat Med. 2003 May;9(5):533-9. Epub 2003 Apr 14.

PMID:
12692540
35.
36.
37.

Molecular epidemiology of tuberculosis.

Burgos MV, Pym AS.

Eur Respir J Suppl. 2002 Jul;36:54s-65s. Review.

38.

A new evolutionary scenario for the Mycobacterium tuberculosis complex.

Brosch R, Gordon SV, Marmiesse M, Brodin P, Buchrieser C, Eiglmeier K, Garnier T, Gutierrez C, Hewinson G, Kremer K, Parsons LM, Pym AS, Samper S, van Soolingen D, Cole ST.

Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3684-9. Epub 2002 Mar 12.

39.

Inactivation of the Mycobacterium tuberculosis Nramp orthologue (mntH) does not affect virulence in a mouse model of tuberculosis.

Domenech P, Pym AS, Cellier M, Barry CE 3rd, Cole ST.

FEMS Microbiol Lett. 2002 Jan 22;207(1):81-6.

40.

The evolution of mycobacterial pathogenicity: clues from comparative genomics.

Brosch R, Pym AS, Gordon SV, Cole ST.

Trends Microbiol. 2001 Sep;9(9):452-8. Review.

PMID:
11553458
41.

Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis.

Pym AS, Domenech P, Honoré N, Song J, Deretic V, Cole ST.

Mol Microbiol. 2001 May;40(4):879-89.

42.

Tools for the population genomics of the tubercle bacilli.

Pym AS, Brosch R.

Genome Res. 2000 Dec;10(12):1837-9. Review. No abstract available.

43.

Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur.

Brosch R, Gordon SV, Buchrieser C, Pym AS, Garnier T, Cole ST.

Yeast. 2000 Jun 30;17(2):111-23.

44.

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.

Churchill DR, Pym AS, Galpin S, Foxall R, Stainsby C, Clarke JR, Kaye S, Bloor S, Larder BA, Wills B, Sun E, Babiker AG, Back DJ, Weber JN.

AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1181-9.

PMID:
10480631
45.

Post DOTS, post genomics: the next century of tuberculosis control.

Pym AS, Cole ST.

Lancet. 1999 Mar 20;353(9157):1004-5. No abstract available.

PMID:
10459929
46.

The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type 1-infected patients.

Adams GB, Pym AS, Poznansky MC, McClure MO, Weber JN.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):551-9.

PMID:
10221532
47.

Hyperlipidaemia following treatment with protease inhibitors in patients with HIV-1 infection.

Churchill DR, Pym AS, Babiker AG, Back DJ, Weber JN.

Br J Clin Pharmacol. 1998 Nov;46(5):518-9. No abstract available.

48.

Pasteurella multocida abcess in an African patient with human immunodeficiency virus infection.

Depraetere K, Colebunders R, Vos L, Pym AS, Ieven M.

Clin Microbiol Infect. 1997 Feb;3(6):700-701. No abstract available.

49.

Reasons for increased incidence of tuberculosis. Audit suggests that undernotification is common.

Pym AS, Churchill DR, Coker RJ, Gleissberg V.

BMJ. 1995 Aug 26;311(7004):570. No abstract available.

Supplemental Content

Support Center